Abcam, ab268523, Recombinant human GST-EML4-ALK protein (Active)

Size: 5µg
Recombinant human GST-EML4-ALK protein (Active) is a Human Fragment protein, in the 1 to 534 aa range, expressed in Baculovirus infected Sf9 cells, with >70%, suitable for SDS-PAGE, FuncS.
Key facts
Purity:>70% SDS-PAGE,
Expression system:Baculovirus infected Sf9 cells,
Tags:Tag free,
Applications:FuncS, SDS-PAGESee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Biologically active:Yes,
Biological activity:The specific activity of ab268523 was 4.2 nmol/min/mg in a peptide kinase assay using IGF1Rtide (KKKSPGEYVNIEFG) as substrate.,
Accession:Q9UM73,
Animal free:No,
Carrier free:No,
Species:Human,
Storage buffer:pH: 7.5Constituents: 25% Glycerol (glycerin, glycerine), 0.87% Sodium chloride, 0.79% Tris HCl, 0.31% Glutathione, 0.004% (R*,R*)-1,4-Dimercaptobutan-2,3-diol, 0.003% EDTA, 0.002% PMSF

Product details:
GST-EML4-ALK fusion protein

Properties and Storage Information:
Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--80°C, Appropriate long-term storage conditions--80°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The ALK EML4 fusion also referred to as EML4-ALK or ALK EML4 is a fusion protein resulting from a chromosomal rearrangement between the genes encoding ALK (anaplastic lymphoma kinase) and EML4 (echinoderm microtubule-associated protein-like 4). This rearrangement generates a fusion gene that translates into a fusion protein commonly found in certain cancers. This protein retains the enzymatic activity of ALK allowing it to act as an aberrant tyrosine kinase. The mass of the EML4-ALK fusion protein typically varies depending on the exact breakpoints involved but it is widely expressed in the cells of lung adenocarcinoma.
Biological function summary
The EML4-ALK fusion protein functions as an oncoprotein promoting uncontrolled cell proliferation and survival. It is not necessarily part of a complex but acts within signaling networks due to its kinase activity. By phosphorylating downstream substrates the EML4-ALK fusion disrupts normal cellular signaling enabling cancerous characteristics in affected cells. Its aberrant activation of signaling pathways can lead to sustained oncogenic signaling bypassing normal growth factor receptor regulation.
Pathways
ALK EML4 fusion interacts within key pathways like the PI3K/AKT and MAPK signaling cascades. These pathways are critical for cell growth survival and metabolism and the presence of EML4-ALK fusion causes constitutive activation promoting oncogenesis. The protein often impacts other signaling proteins such as mTOR and ERK which are downstream effectors within these pathways leading to enhanced cell proliferation and resistance to apoptosis.
The EML4-ALK fusion has a strong connection with non-small cell lung cancer (NSCLC) particularly in patients who are non-smokers or young. It also appears in anaplastic large cell lymphoma (ALCL). Within these conditions the abnormal activity of the fusion protein drives oncogenic processes making it a target for specific therapies like ALK inhibitors. The EML4-ALK fusion-associated cancers sometimes show resistance or less efficacy to standard chemotherapy highlighting the need for targeted approaches in its management.